Lv11
92 积分 2020-08-28 加入
A covalent fragment-based strategy targeting a novel cysteine to inhibit activity of mutant EGFR kinase
1个月前
已完结
Targeting EGFR with molecular degraders as a promising strategy to overcome resistance to EGFR inhibitors
1个月前
已完结
HJM-561, a Potent, Selective, and Orally Bioavailable EGFR PROTAC that Overcomes Osimertinib-Resistant EGFR Triple Mutations
1个月前
已完结
BDTX-1535GoesafterOsimertinibResistance
1个月前
已完结
Next-generation EGFR tyrosine kinase inhibitors to overcome C797S mutation in non-small cell lung cancer (2019–2024)
1个月前
已完结
Catalytic Lysine745 targeting strategy in fourth-generation EGFR tyrosine kinase inhibitors to address C797S mutation resistance
2个月前
已完结
From challenges to solutions: A review of fourth-generation EGFR tyrosine kinase inhibitors to overcome the C797S triple mutation in non-small cell lung cancer
2个月前
已完结
FAK inhibitors in cancer, a patent review – an update on progress
6个月前
已完结
Discovery of ERD-1233 as a Potent and Orally Efficacious Estrogen Receptor PROTAC Degrader for the Treatment of ER+ Human Breast Cancer
6个月前
已完结
Glutamine mimicry suppresses tumor progression through asparagine metabolism in pancreatic ductal adenocarcinoma
1年前
已完结
皖公网安备34019202002308
